GLP-1 Drug Coverage Decisions Reshape Employer Healthcare Spending Calculations

Employers face difficult decisions about covering GLP-1 medications like Ozempic and Wegovy as costs per patient can exceed $15,000 annually. Some organizations are restricting coverage to FDA-approved indications while others embrace the drugs as potentially reducing long-term costs from obesity-related conditions.

What Happened

Pittsburgh Regional Transit’s decision to eliminate GLP-1 coverage for weight loss alone—projected to avoid $1.15 million annually—reflects calculations many employers are making. The decision separates coverage for diabetes treatment (maintained) from weight management (eliminated).

Key Data

PRT projected savings: $1.15 million annually

Annual cost per patient: Often exceeds $15,000

Expert Analysis

“The coverage decision isn’t just about immediate costs. Employers must weigh potential long-term savings from reduced obesity-related conditions against current premium impacts.”

— Benefits Industry Analysis

What’s Next

As more GLP-1 medications reach market and potentially lower prices through competition, coverage decisions will evolve. Employers are watching outcomes data to inform future benefit design.

Frequently Asked Questions

Why are GLP-1 drugs so expensive?

As newer medications under patent protection, GLP-1 drugs face limited competition. Manufacturers price based on demonstrated clinical effectiveness.